↓ Skip to main content

Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis

Overview of attention for article published in JNCI: Journal of the National Cancer Institute, May 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news
2 news outlets
blogs
4 blogs
twitter
21 X users

Citations

dimensions_citation
85 Dimensions

Readers on

mendeley
95 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis
Published in
JNCI: Journal of the National Cancer Institute, May 2018
DOI 10.1093/jnci/djy081
Pubmed ID
Authors

James Yarmolinsky, Carolina Bonilla, Philip C Haycock, Ryan J Q Langdon, Luca A Lotta, Claudia Langenberg, Caroline L Relton, Sarah J Lewis, David M Evans, PRACTICAL Consortium, George Davey Smith, Richard M Martin

Abstract

In the Selenium and Vitamin E Cancer Prevention Trial (SELECT), selenium supplementation (causing a median 114 μg/L increase in circulating selenium) did not lower overall prostate cancer risk, but increased risk of high-grade prostate cancer and type 2 diabetes. Mendelian randomization analysis uses genetic variants to proxy modifiable risk factors and can strengthen causal inference in observational studies. We constructed a genetic instrument comprising 11 single nucleotide polymorphisms robustly (P < 5 × 10-8) associated with circulating selenium in genome-wide association studies. In a Mendelian randomization analysis of 72 729 men in the PRACTICAL Consortium (44 825 case subjects, 27 904 control subjects), 114 μg/L higher genetically elevated circulating selenium was not associated with prostate cancer (odds ratio [OR] = 1.01, 95% confidence interval [CI] = 0.89 to 1.13). In concordance with findings from SELECT, selenium was weakly associated with advanced (including high-grade) prostate cancer (OR = 1.21, 95% CI = 0.98 to 1.49) and type 2 diabetes (OR = 1.18, 95% CI = 0.97 to 1.43; in a type 2 diabetes genome-wide association study meta-analysis with up to 49 266 case subjects and 249 906 control subjects). Our Mendelian randomization analyses do not support a role for selenium supplementation in prostate cancer prevention and suggest that supplementation could have adverse effects on risks of advanced prostate cancer and type 2 diabetes.

X Demographics

X Demographics

The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 95 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 18%
Student > Ph. D. Student 14 15%
Student > Master 9 9%
Student > Doctoral Student 5 5%
Student > Bachelor 5 5%
Other 16 17%
Unknown 29 31%
Readers by discipline Count As %
Medicine and Dentistry 19 20%
Biochemistry, Genetics and Molecular Biology 13 14%
Agricultural and Biological Sciences 8 8%
Nursing and Health Professions 4 4%
Computer Science 3 3%
Other 10 11%
Unknown 38 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 47. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 October 2022.
All research outputs
#889,224
of 25,411,814 outputs
Outputs from JNCI: Journal of the National Cancer Institute
#573
of 7,850 outputs
Outputs of similar age
#19,413
of 342,473 outputs
Outputs of similar age from JNCI: Journal of the National Cancer Institute
#9
of 55 outputs
Altmetric has tracked 25,411,814 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,850 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,473 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.